查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988095

抗瘧疾藥市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、劑型、通路和最終用戶分類）

Antimalarial Drugs Market by Drug Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗瘧疾藥市場價值將達到 18.7 億美元，到 2026 年將成長到 19.9 億美元，到 2032 年將達到 28.4 億美元，複合年成長率為 6.12%。

主要市場統計數據
基準年 2025 18.7億美元
預計年份：2026年 19.9億美元
預測年份 2032 28.4億美元
複合年成長率 (%) 6.12%

清晰簡潔地介紹了影響抗瘧疾藥使用和策略決策的現代臨床、政策和供應鏈環境。

瘧疾仍然是全球面臨的持續性健康挑戰，抗瘧疾藥對於降低疫區人群的發病率和死亡率至關重要。本執行摘要整合了目前影響抗瘧治療的科學、監管和商業性趨勢，重點闡述了臨床實踐、產品可及性和醫療衛生系統準備之間的相互作用。近年來，藥物療效問題、抗藥性標記的出現以及治療指南的不斷更新，三者之間呈現出複雜的相互作用，共同影響著臨床決策和籌資策略。

不斷發展的抗藥性科學、更新的治療策略和供應鏈韌性如何共同重塑抗瘧疾療法的研發、採購和部署。

抗瘧疾藥領域正經歷著由科學進步、政策轉變和市場力量共同驅動的變革。在科學方面，對抗藥性機制和分子監測的深入理解正促使治療指南進行修訂，並引發人們對新型聯合治療的濃厚興趣。同時，診斷技術的改進和綜合病例管理方法的進步正在改變需求模式，推動標靶治療的發展，並減少不合理用藥。

貿易政策和關稅變化對籌資策略、供應商多元化以及促進抗瘧疾藥。

美國在2025年實施的關稅政策，為國際抗瘧疾藥供應體系的採購、生產和成本結構帶來了新的考量。關稅壁壘正在影響採購決策，並可能加速本地化進程，因為買家和製造商需要更具關稅優勢的供應鏈和本地化生產。為此，一些製造商正在考慮遷移生產基地或協商長期契約，以將關稅的影響內部化，從而保護脆弱市場的價格穩定。

針對治療分類、給藥途徑、劑型、通路和最終用戶環境等因素進行詳細的細分分析，進而形成差異化的需求和策略。

市場區隔分析揭示了對產品開發、分銷規劃和臨床導入策略至關重要的關鍵細節。從藥物類別來看，市場可分為青蒿素類聯合治療和非青蒿素類療法。前者包括一些特定的組合，例如蒿甲醚/苯芴醇、蒿甲醚/阿莫地喹、蒿甲醚/甲氟喹和青蒿素/哌喹；後者則包括一些傳統藥物，例如Chloroquine、甲氟喹、伯氨喹和奎寧。了解這些藥物類別中的治療定位和抗藥性特徵對於藥物選擇決策和臨床指南的發展至關重要。

區域流行病學、監管協調和全球主要地區的生產能力如何影響抗瘧疾療法的取得途徑和策略重點。

區域趨勢深刻影響著美洲、歐洲、中東和非洲以及亞太地區的醫療資源取得、監管方式和供應鏈策略，每個地區都具有其獨特的流行病學特徵和醫療衛生系統能力。在美洲，尤其是在局部疫情爆發和邊境地區，重點往往在於採取有針對性的措施、加強監測和維持供應的連續性，與當地製造商的合作以及區域採購機制在確保穩定供應方面發揮著至關重要的作用。

企業策略、夥伴關係和商業實踐決定了誰能夠在複雜的全球市場中可靠地提供有效的抗瘧疾解決方案。

領先企業和機構透過策略性投資、夥伴關係和營運調整，正在塑造抗瘧疾治療的發展方向。創新企業持續投資於新一代化合物和新型給藥平台，而成熟的學名藥生產商則專注於提高生產效率和最佳化成本結構，以滿足流行地區的持續需求。隨著官民合作關係促進後期臨床試驗、技術轉移、生產製造和品質保證等方面的能力建設，合作模式正變得越來越普遍。

為提高抗瘧疾藥整個價值鏈的治療效果、供應鏈韌性、監管協調和相關人員合作，提出切實可行的策略建議。

產業領導者應採取多管齊下的策略，同時提升臨床療效、增強供應韌性並促進相關人員的合作。首先，增加對抗菌藥物抗藥性監測、數據共用和適應性臨床計畫的投入，有助於維持治療價值並促進政策的及時調整。其次，透過區域製造夥伴關係實現價值鏈多元化，並加強灌裝和包裝能力，可以減輕貿易中斷和關稅的影響，同時提高對區域需求的應對力。

採用透明的混合方法研究途徑，結合證據整合、與關鍵相關人員的訪談以及嚴格的檢驗，確保研究結果的可靠性和可操作性。

本執行摘要的研究採用了一種混合方法，將嚴謹的二手資料整合與有針對性的原始研究相結合，以確保其相關性和有效性。二手資料包括同行評審的臨床文獻、監管指導文件和公共衛生報告，這些資料均經過嚴格的評估，以確保調查方法的品質和實際適用性。原始研究包括對臨床醫生、採購專家、製造企業高管和政策顧問進行結構化訪談，以了解實際觀點和實際情況的限制因素。

結論強調，協調的監測、對本地製造的投資以及營運彈性對於維持抗瘧疾治療的有效性至關重要。

總之，目前抗瘧疾藥的現況受到科學、監管和物流等諸多因素複雜交互作用的影響，需要採取協調一致且以證據為基礎的因應措施。抗菌素抗藥性監測、適應性政策制定以及對本地生產和供應鏈系統的定向投資，對於維持療效和確保公平獲取至關重要。相關人員若能將臨床知識與從採購設計到現場分發的營運彈性結合，將更有能力應對新出現的挑戰，並支持永續的疾病控制工作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗瘧疾藥市場：依藥物類別分類

  • 青蒿素類聯合療法
    • Artemester Rumefantrine
    • 阿莫地喹
    • 青蒿琥酯甲氟喹
    • 青蒿素哌喹
  • 非青蒿素類療法
    • Chloroquine
    • 甲氟喹
    • 普里馬金
    • 奎寧

第9章：抗瘧疾藥市場：依給藥途徑分類

  • 注射藥物
  • 口服

第10章：抗瘧疾藥市場（依劑型分類）

  • 注射藥物
  • 懸浮液
  • 藥片

第11章：抗瘧疾藥市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：抗瘧疾藥市場：依最終用戶分類

  • 門診部
  • 診所
  • 醫院

第13章：抗瘧疾藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：抗瘧疾藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗瘧疾藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗瘧疾藥市場

第17章：中國抗瘧疾藥市場

第18章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alkem Laboratories
  • Alliance Pharma
  • Alvizia Health Care
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd.
  • Lincoln Pharmaceuticals
  • Lupin Limited
  • Merck KGaA
  • Mylan
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Group
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Group
  • Zydus Lifesciences Ltd.
Product Code: MRR-F97DD5A7DAEF

The Antimalarial Drugs Market was valued at USD 1.87 billion in 2025 and is projected to grow to USD 1.99 billion in 2026, with a CAGR of 6.12%, reaching USD 2.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.87 billion
Estimated Year [2026] USD 1.99 billion
Forecast Year [2032] USD 2.84 billion
CAGR (%) 6.12%

A clear, concise introduction to the contemporary clinical, policy, and supply chain environment shaping antimalarial drug use and strategic decision-making

Malaria remains a persistent global health challenge, and antimalarial drugs are central to reducing morbidity and mortality in affected populations. This executive summary synthesizes current scientific, regulatory, and commercial dynamics shaping antimalarial therapeutics, emphasizing the intersection of clinical practice, product availability, and health system preparedness. Recent years have witnessed a complex interplay between drug efficacy concerns, emergence of resistance markers, and evolving treatment guidelines, which together influence clinical decision-making and procurement strategies.

Beyond clinical efficacy, the landscape is influenced by manufacturing capacity, supply chain integrity, and policy incentives that determine access in endemic regions. Public-private collaborations and international donor initiatives continue to drive distribution efforts, while national health systems wrestle with integration of new treatment protocols and pharmacovigilance requirements. As a result, stakeholders ranging from clinicians and procurement officers to manufacturers and policymakers must navigate shifting evidence and logistical constraints. This overview provides a concise orientation for decision-makers seeking to understand the contemporary context of antimalarial drugs and to prioritize strategic actions that preserve treatment effectiveness and ensure sustained access.

How evolving resistance science, updated treatment policies, and supply chain resilience are jointly reshaping development, procurement, and deployment of antimalarial therapies

The antimalarial space is undergoing transformative shifts driven by scientific advances, policy change, and market forces. On the scientific front, improved understanding of resistance mechanisms and molecular surveillance has prompted revisions to therapeutic guidance and accelerated interest in novel combination therapies. Concurrently, enhanced diagnostics and integrated case management approaches are altering demand patterns, encouraging targeted treatment and reducing inappropriate drug use.

From a regulatory and policy perspective, rapid updates to national treatment policies have become more common as surveillance data emerges, requiring manufacturers and procurement agencies to be more agile. Commercially, consolidation among generics manufacturers and strategic alliances with research institutions are reshaping supply relationships and capacity planning. Meanwhile, supply chain resilience has risen in priority after recent global disruptions, driving investments in regional manufacturing, buffer stock policies, and diversified sourcing. Taken together, these shifts are redefining how drugs are developed, procured, and deployed, creating both risks and opportunities for stakeholders committed to sustaining effective antimalarial therapy.

Implications of trade policy changes and tariffs on procurement strategies, supplier diversification, and the push toward regional manufacturing for antimalarial supplies

The imposition of tariffs by the United States in 2025 introduced new considerations for procurement, manufacturing, and cost structures within the international antimalarial supply ecosystem. Tariff barriers influence sourcing decisions and may accelerate regionalization efforts as purchasers and manufacturers seek tariff-efficient supply chains and localized production. In response, some manufacturers have evaluated shifting production footprints or negotiating long-term contracts that internalize tariff impacts to protect price stability in vulnerable markets.

Healthcare purchasers and national programs have needed to reassess tender specifications and supplier diversification to mitigate potential disruptions. Moreover, tariff-related changes have reinforced the strategic importance of regional manufacturing hubs and in-country fill-and-finish capabilities, which can reduce exposure to international trade frictions. At the same time, donor agencies and multilateral partners have had to adapt funding models to accommodate altered cost dynamics, prioritizing interventions that preserve access while promoting sustainable local capacity. Overall, tariffs have catalyzed a reevaluation of supply chain strategies and underscored the advantage of flexible procurement approaches that can absorb policy-driven shocks.

Detailed segmentation insights highlighting therapeutic classes, administration routes, formulations, distribution channels, and end-user settings that drive differentiated demand and strategy

Segmentation analysis reveals critical nuances that should inform product development, distribution planning, and clinical adoption strategies. When considering drug class, the market is partitioned between artemisinin-based combination therapies and non-artemisinin therapies, with the former encompassing specific combinations such as artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine, and the latter including classic agents like chloroquine, mefloquine, primaquine, and quinine; understanding therapeutic niches and resistance profiles across those classes is essential for formulary decisions and clinical guidelines.

Route of administration is another differentiator, with oral and injectable modalities presenting distinct use cases: oral formulations are central to outpatient management and mass drug administration campaigns, whereas injectables are critical for severe malaria and inpatient care. Formulation considerations-whether injectables, suspensions, or tablets-affect manufacturing complexity, cold chain needs, and adherence outcomes. Distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, create divergent pathways to end users and require tailored commercial and regulatory approaches. Finally, end user segmentation across ambulatory care centers, clinics, and hospitals highlights where demand concentrates, how treatment protocols vary by setting, and where investments in training and supply chain interventions will have the greatest impact.

How regional epidemiology, regulatory harmonization, and manufacturing capacity across major global regions shape access pathways and strategic priorities for antimalarial therapies

Regional dynamics deeply influence access, regulatory approaches, and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct epidemiological profiles and health system capacities. In the Americas, the focus often lies on targeted control measures, surveillance strengthening, and maintaining supply continuity for localized outbreaks and border areas; partnership with local manufacturers and regional procurement mechanisms plays a role in ensuring steady availability.

In Europe, the Middle East & Africa, regulatory harmonization efforts and donor-supported programs intersect with high-burden settings in parts of Africa, where access and resistance management remain priorities; investments in surveillance infrastructure and capacity building are particularly impactful. Across Asia-Pacific, complex epidemiology and pockets of multidrug resistance have driven innovation in treatment protocols and accelerated adoption of combination therapies, while robust generic manufacturing in parts of the region affects global supply flows. Collectively, these regional patterns necessitate differentiated strategies for policy engagement, procurement design, and local capacity strengthening to match clinical needs and health system realities.

Corporate strategies, partnerships, and operational practices that are determining who can reliably deliver effective antimalarial solutions in complex global markets

Key corporate and institutional behaviors are shaping the trajectory of antimalarial therapeutics through strategic investments, partnerships, and operational adjustments. Innovator companies continue to invest in next-generation compounds and novel delivery platforms, while established generic manufacturers focus on scaling production efficiency and improving cost structures to meet sustained demand in endemic markets. Collaborative models are increasingly common, with public-private partnerships facilitating late-stage clinical studies, technology transfer, and capacity building in manufacturing and quality assurance.

At the same time, contract manufacturers and specialty formulation providers play a vital role in enabling rapid scale-up and in-country fill-and-finish operations. Strategic alliances between pharmaceutical firms and diagnostic developers are also emerging to align treatment with improved case detection. From a commercial perspective, companies that combine robust pharmacovigilance, compliance with international quality standards, and responsive supply chain capabilities are best positioned to support national programs and international donors. Overall, the market rewards organizations that balance R&D innovation with reliable manufacturing and deep operational understanding of endemic markets.

Actionable strategic recommendations for strengthening therapeutic efficacy, supply chain resilience, regulatory alignment, and stakeholder collaboration across the antimalarial value chain

Industry leaders should adopt a multi-pronged strategy that concurrently advances clinical efficacy, supply resilience, and stakeholder collaboration. First, investment in resistance surveillance, data sharing, and adaptive clinical programs will preserve therapeutic value and inform timely policy adaptations. Second, diversifying supply chains through regional manufacturing partnerships and strengthened fill-and-finish capabilities will reduce exposure to trade disruptions and tariffs while improving responsiveness to localized demand.

Beyond procurement and manufacturing, organizations should prioritize integrated product stewardship, coupling reliable pharmacovigilance with provider education to sustain appropriate use. Engaging proactively with regulatory bodies and multilateral donors enables alignment of procurement frameworks with public health goals. Finally, adopting digital tools for demand forecasting, inventory visibility, and quality monitoring enhances decision-making across the product lifecycle. Taken together, these actions create a resilient approach that supports effective treatment delivery and long-term viability of antimalarial interventions.

A transparent mixed-methods research approach combining evidence synthesis, primary stakeholder interviews, and rigorous validation to ensure credible insights and practical relevance

The research underpinning this executive summary deployed a mixed-methods approach combining rigorous secondary evidence synthesis with targeted primary inquiry to ensure validity and relevance. Secondary inputs included peer-reviewed clinical literature, regulatory guidance documents, and public health reports that were critically appraised for methodological quality and applicability to practice. Primary research involved structured interviews with clinicians, procurement specialists, manufacturing executives, and policy advisors to capture operational perspectives and real-world constraints.

Data triangulation and cross-validation techniques were applied to reconcile divergent sources and to identify consistent patterns. Attention was paid to temporal factors and recent policy changes to ensure the analysis reflects the most current realities. Where quantitative data were limited, qualitative insights were used to contextualize trends and infer strategic implications. Finally, quality assurance measures, including expert peer review and methodological transparency, were implemented to enhance credibility and to provide stakeholders with confidence in the report's findings and recommendations.

Concluding insights emphasizing the imperative of coordinated surveillance, regional manufacturing investments, and operational agility to sustain antimalarial treatment effectiveness

In conclusion, the antimalarial drugs landscape is defined by a confluence of scientific, regulatory, and logistical dynamics that require coordinated, evidence-driven responses. Resistance surveillance, adaptive policy-making, and targeted investments in regional manufacturing and supply chain systems are central to preserving treatment effectiveness and ensuring equitable access. Stakeholders who integrate clinical intelligence with operational agility - from procurement design to on-the-ground distribution - will be better positioned to respond to emerging challenges and to support sustainable disease control efforts.

Moving forward, the emphasis should remain on collaboration across public, private, and philanthropic actors to align incentives, share data, and build capacity where it matters most. By focusing on resilient supply chains, responsive regulatory engagement, and stewardship of existing therapeutics while fostering innovation, the global community can sustain progress against malaria and protect vulnerable populations from preventable illness and death.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimalarial Drugs Market, by Drug Class

  • 8.1. Artemisinin Based Combination Therapy
    • 8.1.1. Artemether Lumefantrine
    • 8.1.2. Artesunate Amodiaquine
    • 8.1.3. Artesunate Mefloquine
    • 8.1.4. Dihydroartemisinin Piperaquine
  • 8.2. Non Artemisinin Therapies
    • 8.2.1. Chloroquine
    • 8.2.2. Mefloquine
    • 8.2.3. Primaquine
    • 8.2.4. Quinine

9. Antimalarial Drugs Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral

10. Antimalarial Drugs Market, by Formulation

  • 10.1. Injectables
  • 10.2. Suspensions
  • 10.3. Tablets

11. Antimalarial Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Antimalarial Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Antimalarial Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimalarial Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimalarial Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antimalarial Drugs Market

17. China Antimalarial Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Alkem Laboratories
  • 18.7. Alliance Pharma
  • 18.8. Alvizia Health Care
  • 18.9. Bayer AG
  • 18.10. Cipla Inc.
  • 18.11. Dr. Reddy's Laboratories
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. GlaxoSmithKline plc
  • 18.14. Glenmark Pharmaceuticals
  • 18.15. Hikma Pharmaceuticals PLC
  • 18.16. Ipca Laboratories Ltd.
  • 18.17. Lincoln Pharmaceuticals
  • 18.18. Lupin Limited
  • 18.19. Merck KGaA
  • 18.20. Mylan
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Sanofi Group
  • 18.24. Strides Pharma Science Limited
  • 18.25. Sun Pharmaceutical Industries Ltd.
  • 18.26. Takeda Pharmaceutical Company
  • 18.27. Teva Pharmaceuticals Industries Ltd.
  • 18.28. Zydus Group
  • 18.29. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)